Close Menu

stock delisting

NEW YORK (GenomeWeb News) – BG Medicine said after the close of the market Friday that it has been notified by Nasdaq for the third time in less than a year that it does not fulfill a requirement for continued listing on the exchange.

NEW YORK (GenomeWeb News) – Accelrys said on Friday that it has been notified by Nasdaq that the company does not comply with a listing requirement that its audit committee be comprised of three independent directors.

NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Pressure BioSciences has been delisted by the Nasdaq Stock market after failing to come into compliance with two requirements for continued listing.

Pressure Bio said that the placement is the first closing of a $6 million private placement and additional closings are anticipated to occur during the first half of the year.

Rosetta received an extension to come into compliance with one regulation, but it was notified this week that it is now not in compliance with the $1 per share closing price requirement.

CombiMatrix will voluntarily apply to have its stock transferred to the Nasdaq Capital Market from the Nasdaq Global Market following a recent delisting warning.

In a letter to the company, Nasdaq said that the firm is not in compliance with requirements that its stock equity be at least $10 million to remain trading on the Nasdaq Global Market.

Because the company considered it unlikely to meet the Nasdaq minimum market value requirement, it withdrew its appeal to Nasdaq on Nov. 12, resulting in the delisting on Nov. 16.


A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.